Skip to content
Riskpilot
← Back to search
Sign in
Get full access
NextCell Pharma AB
AB
Active
Org 5569658361
Hälsovägen 7, 141 57
Huddinge
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2014 · 12 years old
5-9 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
NextCell Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
3M
6M
9M
13M
4M
2020
4M
2021
6M
2022
10M
2023
11M
2024
EBITDA
SEK millions
43M
19M
-5M
-29M
-53M
-17M
2020
34M
+300%
2021
-35M
-203%
2022
-41M
-17%
2023
-42M
-2%
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
3 565
3 912
5 589
10 113
10 665
Staff expenses
—
—
—
—
—
EBITDA
−17 305
34 259
−34 567
−40 554
−42 197
Depreciation & amort.
−397
−437
−457
−448
−975
EBIT
−17 702
33 822
−35 024
−41 002
−43 172
Net financials
22
264
469
1 190
1 213
Profit before tax
−17 681
0
−34 554
−39 812
−41 960
Tax
−0
−0
−0
−0
−0
Net profit
−17 681
34 086
−34 554
−39 812
−41 960
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
29 774
155 626
124 655
88 827
81 288
Equity
26 218
150 093
115 539
75 727
67 599
Long-term debt
1 381
1 576
2 185
3 020
3 816
Short-term debt
2 175
3 957
6 932
10 080
9 873
Total debt
3 556
5 533
9 117
13 100
13 689
Financial ratios
5-year trend
EBITDA margin
-395.7%
This company
15.8%
Market median
-2604% vs market
2020
2024
Equity ratio
83.2%
This company
38.2%
Market median
+118% vs market
2020
2024
Return on equity
-62.1%
This company
18.4%
Market median
-438% vs market
2020
2024
Net profit margin
-393.4%
This company
8.1%
Market median
-4957% vs market
2020
2024
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
2020
2024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
View
PDF
More on NextCell Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
